Whilst heart failure medicines should be titrated to evidence-based target doses [4], we found that staff did not always agree with providing a target dose for ACE inhibitors, angiotensin receptor blockers, and/or beta-blockers in the patient’s fold-out medicines chart. The gene discussed is ACE; the disease is heart failure.